0.00
전일 마감가:
$8.16
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$564.26M
수익:
-
순이익/손실:
$-30.04M
주가수익비율:
0.00
EPS:
-1.58
순현금흐름:
$-27.38M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
Regulus Therapeutics Inc Stock (RGLS) Company Profile
명칭
Regulus Therapeutics Inc
전화
858-202-6300
주소
4224 CAMPUS POINT COURT, SAN DIEGO, CA
RGLS을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
RGLS
Regulus Therapeutics Inc
|
0.00 | 564.26M | 0 | -30.04M | -27.38M | -1.58 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Regulus Therapeutics Inc Stock (RGLS) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-03-27 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
2024-08-02 | 개시 | Oppenheimer | Outperform |
2024-03-18 | 개시 | Leerink Partners | Outperform |
2018-03-28 | 개시 | B. Riley FBR, Inc. | Neutral |
2018-01-05 | 개시 | Leerink Partners | Outperform |
2017-06-13 | 재확인 | Chardan Capital Markets | Buy |
2017-03-06 | 재확인 | Wedbush | Outperform |
2017-01-30 | 다운그레이드 | Needham | Buy → Hold |
2017-01-30 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
2016-12-07 | 재확인 | Chardan Capital Markets | Buy |
2016-11-02 | 재확인 | Needham | Buy |
2016-07-25 | 재확인 | Chardan Capital Markets | Buy |
2016-06-28 | 재확인 | Chardan Capital Markets | Buy |
2016-06-28 | 재확인 | FBR Capital | Outperform |
2016-06-28 | 재확인 | Needham | Buy |
2016-06-07 | 재확인 | Chardan Capital Markets | Buy |
2016-04-13 | 개시 | Chardan Capital Markets | Buy |
2015-12-04 | 개시 | Wells Fargo | Outperform |
2015-06-09 | 개시 | Guggenheim | Buy |
2015-04-21 | 재개 | FBR Capital | Outperform |
2014-11-24 | 개시 | Deutsche Bank | Buy |
2014-08-07 | 재확인 | FBR Capital | Outperform |
2013-08-14 | 재확인 | Needham | Buy |
모두보기
Regulus Therapeutics Inc 주식(RGLS)의 최신 뉴스
Insider Buying: Preston Klassen Acquires 12,000 Shares of Regulu - GuruFocus
Insider Buying: Preston Klassen Acquires 12,000 Shares of Regulus Therapeutics Inc (RGLS) - GuruFocus
Regulus Therapeutics: An Undervalued Buy, With A $0.90 CVR And A $7 Payout (NASDAQ:RGLS) - Seeking Alpha
Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis - GlobeNewswire Inc.
Novartis emerged victorious in multi-month pursuit of Regulus and potential kidney blockbuster, filing shows - Fierce Pharma
Novartis arm commences tender offer to buy Regulus Therapeutics - Medical Dialogues
Novartis won bidding war for kidney drug as Regulus' top three execs expect to make over $100M combined - Endpoints News
Novartis announces commencement of tender offer to acquire Regulus Therapeutics - The Manila Times
Novartis Announces Commencement Of Tender Offer To Acquire Regulus Therapeutics - marketscreener.com
Novartis Launches Tender Offer for Regulus Therapeutics Takeover - MarketScreener
Regulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - Seeking Alpha
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, XAGE, SSBK on Behalf of Shareholders - TradingView
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Kronos Bio, Inc. (NasdaqKRON), Regulus Therapeutics Inc. (Nasdaq – RGLS), Longevity Health Holdings, Inc. (NasdaqXAGE), Southern States Bancshare - TradingView
Latham and Covington Advise on Novartis’s Acquisition of Regulus - Law Street Media
Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors - The Globe and Mail
Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Acquired by Barclays PLC - Defense World
Regulus Therapeutics (NASDAQ:RGLS) Now Covered by StockNews.com - Defense World
Regulus Therapeutics to be Acquired by Novartis - TipRanks
Regulus: Q1 Earnings Snapshot - Norwalk Hour
Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates - StreetInsider
Regulus (RGLS) to Be Acquired by Novartis, Extending Cash Runway - GuruFocus
Regulus (RGLS) to Be Acquired by Novartis, Extending Cash Runway | RGLS Stock News - GuruFocus
Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Acquired by Renaissance Technologies LLC - Defense World
Novartis to buy Regulus Therapeutics for as much as $1.7 billion - MSN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, PPBI, COEP on Behalf of Shareholders - marketscreener.com
What is Leerink Partnrs’ Estimate for RGLS Q1 Earnings? - Defense World
REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc.RGLS - Business Wire
Novartis (NVS) To Acquire Regulus Therapeutics in $0.8 Billion Deal - GuruFocus
Regulus Therapeutics Stock Skyrockets On $1.7B Acquisition Offer From Novartis - MSN
Taxation With Representation: Goodwin, Haynes Boone - Law360
Novartis to acquire San Diego-based Regulus in deal worth up to $1.7B - MSN
Novartis Buys Regulus, Boosting Biotech Shares Significantly - Finimize
Regulus (RGLS) Downgraded Following Acquisition Agreement | RGLS Stock News - GuruFocus
This Parsons Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday - Benzinga
Regulus Therapeutics (RGLS) Downgraded by Wells Fargo | RGLS Sto - GuruFocus
Novartis Acquires Regulus Therapeutics for $800 Million - GuruFocus
Regulus CVR may be worth $3-$4 a share in Novartis dealanalyst - Seeking Alpha
New $1.7b Novartis acquisition to advance novel microRNA inhibitor - marketscreener.com
Switzerland: Novartis acquires Regulus Therapeutics for up to US$1.7bn - Investors in Healthcare
Leerink Downgrades Regulus Therapeutics to Market Perform From Outperform, Adjusts Price Target to $7 From $6 - marketscreener.com
Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead - MSN
Novartis to acquire US-based Regulus Therapeutics for $1.7bn - World Pharmaceutical Frontiers
Novartis to Acquire Regulus Therapeutics in $1.7 Billion Deal - GuruFocus
Regulus (RGLS) Surges on Acquisition by Novartis for $1.7 Billio - GuruFocus
Regulus Therapeutics Inc (RGLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):